MX2011009669A - Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. - Google Patents

Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.

Info

Publication number
MX2011009669A
MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A
Authority
MX
Mexico
Prior art keywords
influence
excipients
pharmaceutical composition
controlled release
coating
Prior art date
Application number
MX2011009669A
Other languages
English (en)
Inventor
Michael Gottschalk
Hans Baer
Thomas Fuerst
Gerhard Renner
Thomas Rupp
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2011009669A publication Critical patent/MX2011009669A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención trata sobre una composición farmacéutica de liberación controlada, que consta de un núcleo, que consta de un ingrediente farmacéutico activo, donde el núcleo está revestido por una capa de revestimiento que proporciona resistencia y que tiene el efecto de proporcionar el perfil de liberación del ingrediente farmacéutico activo para que sea resistente a la influencia del etanol, en donde la capa de revestimiento que proporciona resistencia al etanol consta de al menos 70% por peso de una mezcla de una porción polimérica a) y una porción de excipientes b), donde la porción polimérica a) está presente en una cantidad de al menos 3.0% por peso calculada en el peso del núcleo y donde la porción polimérica a) consta de una mezcla de polímeros a1) y a2) con a1) 60 a 99% por peso, con base en el peso en seco de la mezcla polimérica, de un polímero de vinilo o un copolímero de vinilo esencialmente neutral insoluble en agua, y a2) 1 a 40% por peso, con base en el peso seco de la mezcla polimérica, de un copolímero amino (met) acrilato, que es soluble en un medio acuoso amortiguado hasta de ph 4.0 e insoluble al menos por encima de ph 5.0 y la porción de excipientes b) que consta de los excipientes b1) 60 a 250% por peso de un lubricante inerte no poroso b2) 0.1 a 25% por peso de un emulsionante y además o de manera alternativa a b2) b3) 0.1 a 30% por peso de un plastificante y de forma opcional b4) 1 - 35% por peso de un compuesto celulósico. donde los excipientes de la porción de excipientes b) se calculan en peso en seco de la porción polimérica a).
MX2011009669A 2009-03-18 2009-03-18 Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. MX2011009669A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/053177 WO2010105673A1 (en) 2009-03-18 2009-03-18 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients

Publications (1)

Publication Number Publication Date
MX2011009669A true MX2011009669A (es) 2011-12-14

Family

ID=40752823

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009669A MX2011009669A (es) 2009-03-18 2009-03-18 Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.

Country Status (10)

Country Link
US (1) US20110311631A1 (es)
EP (1) EP2408437A1 (es)
JP (1) JP5619131B2 (es)
KR (1) KR20120003436A (es)
CN (1) CN102365083A (es)
BR (1) BRPI0924427A2 (es)
CA (1) CA2755814A1 (es)
IL (1) IL214612A0 (es)
MX (1) MX2011009669A (es)
WO (1) WO2010105673A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CN103002882B (zh) 2010-05-10 2016-03-02 欧洲凯尔特公司 不含活性剂之颗粒及包含其之片剂的制备
EA201291211A1 (ru) 2010-05-10 2013-05-30 Эро-Селтик С.А. Фармацевтические композиции, содержащие гидроморфон и налоксон
SI2720682T1 (sl) * 2011-06-17 2017-05-31 Evonik Roehm Gmbh Sestavek za oplaščenje primeren za farmacevtske ali nutracevtske dozirne oblike
SI2720681T1 (sl) 2011-06-17 2017-03-31 Evonik Roehm Gmbh Sestavek za oplaščenje primeren za farmacevtske ali nutracevtske dozirne oblike
RU2649806C2 (ru) 2011-06-17 2018-04-04 Эвоник Рем ГмбХ Желудочно-резистентная фармацевтическая или нутрицевтическая композиция с устойчивостью к воздействию этанола
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US10053597B2 (en) 2013-01-18 2018-08-21 Basf Se Acrylic dispersion-based coating compositions
JP6150564B2 (ja) * 2013-03-08 2017-06-21 杏林製薬株式会社 口腔内速崩壊性錠剤
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
KR102194174B1 (ko) 2013-11-13 2020-12-23 유로-셀티큐 에스.에이. 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106727435B (zh) * 2016-12-26 2020-06-02 浙江工业大学 一种美托洛尔缓释胶囊及其制备方法
JP2020515606A (ja) * 2017-03-31 2020-05-28 アキュラ・ファーマシューティカルズ・インコーポレーテッド 医薬品有効成分の自己調節放出のための方法及び組成物
WO2019052845A1 (en) 2017-09-14 2019-03-21 Evonik Röhm Gmbh POLYMER AND PHARMACEUTICAL FORM WITH PROLONGED RELEASE PROPERTIES AND RESISTANCE TO THE INFLUENCE OF ETHANOL
MX2020009385A (es) 2018-03-09 2020-10-28 Evonik Operations Gmbh Mezcla de polimeros con resistencia a la influencia del etanol.
KR102138253B1 (ko) * 2018-08-17 2020-07-29 한국유나이티드제약 주식회사 실로스타졸 서방성 제제
JP7472116B2 (ja) * 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
CN112294777B (zh) * 2020-11-04 2022-07-05 南京康川济医药科技有限公司 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用
WO2023280962A1 (en) * 2021-07-09 2023-01-12 Evonik Operations Gmbh Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法
WO2023224097A1 (ja) * 2022-05-18 2023-11-23 東和薬品株式会社 膜形成用組成物、膜状組成物及びその利用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
WO1998026767A2 (en) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
DE19918435A1 (de) * 1998-07-23 2000-01-27 Roehm Gmbh Überzugs- und Bindemittel für orale oder dermale Arzneiformen
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
US7348028B2 (en) * 2002-09-09 2008-03-25 Kenneth Stephen Albert Chronotherapeutic diltiazem formulations and the administration thereof
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MXPA06004700A (es) * 2003-10-31 2006-07-05 Hexal Ag Formulacion conteniendo agente farmaceutico comprendiendo un recubrimiento.
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
CA2637755A1 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
CN101801350A (zh) * 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 抗滥用药物、使用方法和制备方法
CA2699227C (en) * 2007-09-21 2014-12-02 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol

Also Published As

Publication number Publication date
IL214612A0 (en) 2011-09-27
JP5619131B2 (ja) 2014-11-05
CN102365083A (zh) 2012-02-29
JP2012520832A (ja) 2012-09-10
US20110311631A1 (en) 2011-12-22
KR20120003436A (ko) 2012-01-10
WO2010105673A1 (en) 2010-09-23
BRPI0924427A2 (pt) 2016-01-26
CA2755814A1 (en) 2010-09-23
EP2408437A1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
MX2011009669A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.
MX2011009667A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes.
MX347227B (es) Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol.
WO2010064126A3 (en) Controlled release dosage forms
BRPI0720626A2 (pt) Composição formadora de película, nanopartículas modificadas, revestimento resistente a risco, usos de um copolímero segmentado, e de nanopartículas modificadas
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
BRPI0823128A2 (pt) Composição farmacêutica de liberação controlada dependente do ph para não opioides com resistência contra a influência de etanol.
MX2017006858A (es) Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol.
WO2009123759A3 (en) Therapeutic uses of biocompatible biogel compositions
MX2017015465A (es) Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol.
MX358196B (es) Composicion farmaceutica o nutraceutica con caracteristica de liberacion sostenida y con resistencia contra la influencia del etanol.
WO2009121970A3 (de) Schichtmaterial
WO2010005732A8 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
WO2010106314A3 (en) Formulation comprising avermectin particles coated with a photo - protecting agent
MX356579B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
MX2012010229A (es) Forma de dosis de liberacion modificada.
EP3500634A4 (en) BENZOPHENONE DERIVATIVE, AQUEOUS COPOLYMER DISPERSION, AND AQUEOUS COATING COMPOSITION
WO2014179615A3 (en) Biodegradable copolymers, forming and using same
WO2012092486A3 (en) Modified release benzimidazole formulations
EP2522348A4 (en) COATED PREPARATION CONTAINING ATROVASTATIN
WO2011103397A3 (en) Rechargeable long-term antifungal denture materials
WO2013102842A3 (en) Device and composition for drug release
TR201900220T4 (tr) Ani ilaç salım kompozisyonları.
BR112012027447A2 (pt) polímero indigerível: revestimentos de filme à base de acetato de amido para veiculação de fármaco para o cólon

Legal Events

Date Code Title Description
FG Grant or registration